… The focus of this study was to assess CINV prophylaxis given with MEC regimens that did
not incorporate an NK1 antagonist or … This study evaluated the efficacy of the 5-HT3 receptor …

… 3 receptor antagonists (5-HT3 RA) dual regimen is the standard … treated with a dual regimen
of dexamethasone and 5-HT3 RA for … FOLFIRI regimen: irinotecan 180 mg/m 2 , intravenous …

… ), which compared 12 different antiemetic regimens: serotonin‐3 receptor antagonist (5HT3), …
Moderately emetogenic chemotherapy, with the emesis occurrence between 30% to 90%, …

… emetogenicity of a regimen may vary over the cycle; and (iv) … tract, the serotonin release can
trigger the emetic response via … regimens of 5-HT3 antagonist plus dexamethasone, 5-HT3 …

… emetogenic chemotherapy (HEC), moderately emetogenic … The studies were considered
high risk if they exhibited … cancer patients receiving HEC and MEC regimes. In the present meta-…

… -drug regimen (aprepitant + serotonin receptor antagonist (… of the dosage, in the moderately
emetogenic category (30–90%) [4]… , we will review the literature for the emetogenicity and the …

… regimens for highly emetogenic chemotherapy and moderately emetogenic chemotherapy
with a high risk of delayed CINV include a serotonin antagonist, dexamethasone and …

… receiving moderately emetogenic chemotherapy (MEC) and … antagonist and in high doses
as a serotonin antagonist. The … a 3-day oral regimen of aprepitant in the prevention of CINV in …

… dexamethasone on Day 1 followed by 6.6 mg intravenous … 3 receptor antagonist has been
the recommended regimen of … , not only dopamine and serotonin that are known mediators of …

… effective than another, and the retrospective analysis was … of moderately to highly emetogenic
chemotherapy regimens, but … of 1 mg iv granisetron due to a lack of studies comparing this …